Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sensus Healthcare to Present at the Raymond James Inaugural Life Sciences and MedTech Conference

SRTS

BOCA RATON, Fla., June 10, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, CEO of the Company, will present a corporate overview at the Raymond James Inaugural Life Sciences and MedTech Conference on Wednesday, June 19 at 2:25 p.m. Eastern time.  The conference will be held June 18-19, 2019 at the Lotte New York Palace Hotel in New York City.

Mr. Sardano’s presentation will be webcast live and available for replay in the Investor Relations section of the Company’s website at www.sensushealthcare.com.

About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ robotic radiation oncology system provides targeted intraoperative triple-modulated radiotherapy (IORT) and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, with a single dose. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit https://www.sensushealthcare.com.

Investor Contact:
Kim Sutton Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com

Media Contacts:
Caitlin Kasunich / Brittany Tibaldi
KCSA Strategic Communications
212-896-1241 / 347-487-6794
ckasunich@kcsa.com / btibaldi@kcsa.com 

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today